381 related articles for article (PubMed ID: 26639960)
1. Empirically Defining Trajectories of Late-Life Cognitive and Functional Decline.
Hochstetler H; Trzepacz PT; Wang S; Yu P; Case M; Henley DB; Degenhardt E; Leoutsakos JM; Lyketsos CG
J Alzheimers Dis; 2016; 50(1):271-82. PubMed ID: 26639960
[TBL] [Abstract][Full Text] [Related]
2. Longitudinal Trajectories of Clinical Decline in Amyloid Positive and Negative Populations.
Trzepacz PT; Hochstetler H; Wang S; Yu P; Case M; Henley DB; Degenhardt E; Leoutsakos JM; Lyketsos CG
J Prev Alzheimers Dis; 2016; 3(2):92-100. PubMed ID: 29210444
[TBL] [Abstract][Full Text] [Related]
3. Cerebral atrophy, apolipoprotein E varepsilon4, and rate of decline in everyday function among patients with amnestic mild cognitive impairment.
Okonkwo OC; Alosco ML; Jerskey BA; Sweet LH; Ott BR; Tremont G;
Alzheimers Dement; 2010 Sep; 6(5):404-11. PubMed ID: 20813341
[TBL] [Abstract][Full Text] [Related]
4. Cognitive Impairment Precedes and Predicts Functional Impairment in Mild Alzheimer's Disease.
Liu-Seifert H; Siemers E; Price K; Han B; Selzler KJ; Henley D; Sundell K; Aisen P; Cummings J; Raskin J; Mohs R;
J Alzheimers Dis; 2015; 47(1):205-14. PubMed ID: 26402769
[TBL] [Abstract][Full Text] [Related]
5. Utility of combinations of biomarkers, cognitive markers, and risk factors to predict conversion from mild cognitive impairment to Alzheimer disease in patients in the Alzheimer's disease neuroimaging initiative.
Gomar JJ; Bobes-Bascaran MT; Conejero-Goldberg C; Davies P; Goldberg TE;
Arch Gen Psychiatry; 2011 Sep; 68(9):961-9. PubMed ID: 21893661
[TBL] [Abstract][Full Text] [Related]
6. Subtle Cognitive Decline and Biomarker Staging in Preclinical Alzheimer's Disease.
Edmonds EC; Delano-Wood L; Galasko DR; Salmon DP; Bondi MW;
J Alzheimers Dis; 2015; 47(1):231-42. PubMed ID: 26402771
[TBL] [Abstract][Full Text] [Related]
7. Modelling Decline in Cognition to Decline in Function in Alzheimer's Disease.
Karcher H; Savelieva M; Qi L; Hummel N; Caputo A; Risson V; Capkun G; Alzheimer's Disease Neuroimaging Initiative
Curr Alzheimer Res; 2020; 17(7):635-657. PubMed ID: 33032508
[TBL] [Abstract][Full Text] [Related]
8. Rates of diagnostic transition and cognitive change at 18-month follow-up among 1,112 participants in the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing (AIBL).
Ellis KA; Szoeke C; Bush AI; Darby D; Graham PL; Lautenschlager NT; Macaulay SL; Martins RN; Maruff P; Masters CL; McBride SJ; Pike KE; Rainey-Smith SR; Rembach A; Robertson J; Rowe CC; Savage G; Villemagne VL; Woodward M; Wilson W; Zhang P; Ames D;
Int Psychogeriatr; 2014 Apr; 26(4):543-54. PubMed ID: 24252258
[TBL] [Abstract][Full Text] [Related]
9. Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study.
Villemagne VL; Burnham S; Bourgeat P; Brown B; Ellis KA; Salvado O; Szoeke C; Macaulay SL; Martins R; Maruff P; Ames D; Rowe CC; Masters CL;
Lancet Neurol; 2013 Apr; 12(4):357-67. PubMed ID: 23477989
[TBL] [Abstract][Full Text] [Related]
10. Potential Implications of Slowing Disease Progression in Amyloid-Positive Early Alzheimer's Disease: Estimates from Real-World Data.
Chandler J; Done N; Desai U; Georgieva M; Gomez-Lievano A; Ye W; Zhao A; Eid D; Hilts A; Kirson N; Schilling T
J Prev Alzheimers Dis; 2024; 11(2):310-319. PubMed ID: 38374737
[TBL] [Abstract][Full Text] [Related]
11. Apolipoprotein ɛ4 is Associated with Dementia and Cognitive Impairment Predominantly Due to Alzheimer's Disease and Not with Vascular Cognitive Impairment: A Singapore-Based Cohort.
Chai YL; Yeo HK; Wang J; Hilal S; Ikram MK; Venketasubramanian N; Wong BS; Chen CL
J Alzheimers Dis; 2016; 51(4):1111-8. PubMed ID: 26923016
[TBL] [Abstract][Full Text] [Related]
12. Varying strength of cognitive markers and biomarkers to predict conversion and cognitive decline in an early-stage-enriched mild cognitive impairment sample.
Egli SC; Hirni DI; Taylor KI; Berres M; Regeniter A; Gass A; Monsch AU; Sollberger M
J Alzheimers Dis; 2015; 44(2):625-33. PubMed ID: 25322924
[TBL] [Abstract][Full Text] [Related]
13. Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials.
Grundman M; Petersen RC; Ferris SH; Thomas RG; Aisen PS; Bennett DA; Foster NL; Jack CR; Galasko DR; Doody R; Kaye J; Sano M; Mohs R; Gauthier S; Kim HT; Jin S; Schultz AN; Schafer K; Mulnard R; van Dyck CH; Mintzer J; Zamrini EY; Cahn-Weiner D; Thal LJ;
Arch Neurol; 2004 Jan; 61(1):59-66. PubMed ID: 14732621
[TBL] [Abstract][Full Text] [Related]
14. Longitudinal Trajectories of Informant-Reported Daily Functioning in Empirically Defined Subtypes of Mild Cognitive Impairment.
Thomas KR; Edmonds EC; Delano-Wood L; Bondi MW
J Int Neuropsychol Soc; 2017 Jul; 23(6):521-527. PubMed ID: 28487004
[TBL] [Abstract][Full Text] [Related]
15. Clinical predictors of progression to Alzheimer disease in amnestic mild cognitive impairment.
Fleisher AS; Sowell BB; Taylor C; Gamst AC; Petersen RC; Thal LJ;
Neurology; 2007 May; 68(19):1588-95. PubMed ID: 17287448
[TBL] [Abstract][Full Text] [Related]
16. The structural MRI markers and cognitive decline in prodromal Alzheimer's disease: a 2-year longitudinal study.
Wei H; Kong M; Zhang C; Guan L; Ba M;
Quant Imaging Med Surg; 2018 Nov; 8(10):1004-1019. PubMed ID: 30598878
[TBL] [Abstract][Full Text] [Related]
17. Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer's disease.
Lim YY; Maruff P; Pietrzak RH; Ames D; Ellis KA; Harrington K; Lautenschlager NT; Szoeke C; Martins RN; Masters CL; Villemagne VL; Rowe CC;
Brain; 2014 Jan; 137(Pt 1):221-31. PubMed ID: 24176981
[TBL] [Abstract][Full Text] [Related]
18. AD dementia risk in late MCI, in early MCI, and in subjective memory impairment.
Jessen F; Wolfsgruber S; Wiese B; Bickel H; Mösch E; Kaduszkiewicz H; Pentzek M; Riedel-Heller SG; Luck T; Fuchs A; Weyerer S; Werle J; van den Bussche H; Scherer M; Maier W; Wagner M;
Alzheimers Dement; 2014 Jan; 10(1):76-83. PubMed ID: 23375567
[TBL] [Abstract][Full Text] [Related]
19. Large intracranial volume accelerates conversion to dementia in males and APOE4 non-carriers with mild cognitive impairment.
An H; Son SJ; Cho S; Cho EY; Choi B; Kim SY;
Int Psychogeriatr; 2016 May; 28(5):769-78. PubMed ID: 26674540
[TBL] [Abstract][Full Text] [Related]
20. Japanese and North American Alzheimer's Disease Neuroimaging Initiative studies: Harmonization for international trials.
Iwatsubo T; Iwata A; Suzuki K; Ihara R; Arai H; Ishii K; Senda M; Ito K; Ikeuchi T; Kuwano R; Matsuda H; ; Sun CK; Beckett LA; Petersen RC; Weiner MW; Aisen PS; Donohue MC;
Alzheimers Dement; 2018 Aug; 14(8):1077-1087. PubMed ID: 29753531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
